SBIR Phase I: An Electronically Activated Antimicrobial Catheter

该小型企业创新研究第一阶段项目提出了一种降低医疗设备相关感染率的新方法。 2013年全球导尿管市场估计为24亿美元，美国市场为11亿美元。 与导管相关尿路感染（CUTI）相关的平均医疗保健系统治疗成本估计为每次感染500至1，000美元，或整个市场每年5亿至10亿美元。该项目将支持开发一种Foley导管，预计可显著降低这些脑梗死的发生率。该项目的智力价值是开发了一种新技术，该技术可在器械表面附近释放高浓度的抗菌银离子。 在本项目中，我们将生产一种抗菌Foley导管，该导管采用了公司的专有技术，与现有器械相比，可显著改善抗菌控制。本I期项目的目的是生产一种电子激活导管，该导管将为所有受试细菌菌种提供比当前市场领先的抗菌导管至少3个对数的额外细菌计数减少。

This Small Business Innovation Research Phase I project advances a new approach for reducing infection rates associated with medical devices. The global urinary catheters market in 2013 was estimated at $2.4 billion, and the United States market was $1.1 billion. The average resulting healthcare system treatment cost related to catheter-associated urinary tract infections (CAUTIs) is estimated between $500 and $1,000 for each infection or between $500 million and $1 billion annually for the total market. This project will support development of a Foley catheter that is expected to significantly reduce the incidence of these CAUTIs. The intellectual merit of this project is the development of a novel technology that results in the release of a high concentration of antimicrobial silver ions near the surface of the device. In this project, we will generate an antimicrobial Foley catheter that incorporates the company's proprietary technology so as to provide for significantly improved antimicrobial control compared to existing devices. The objective of this Phase I project is to produce an electronically activated catheter that will provide a minimum of 3-log additional reduction in bacterial count over the current market-leading antimicrobial catheter, for all bacterial species tested.